The study, published March 28 in Discovery Medicine, also found that these “persister” Lyme bacteria were resistant to standard single-antibiotic Lyme treatments currently used to treat Lyme patients, while a three-antibiotic cocktail eradicated the Lyme bacteria in the mouse model.
For their study, the scientists isolated slow-growth forms of the Lyme bacterium, Borrelia burgdorferi. They found that, compared to normal fast-growth forms, the slow-growing forms caused more severe arthritis-like symptoms and resisted standard antibiotic treatment in test tube as well as in a mouse model. The scientists found that a combination of three antibiotics—daptomycin, doxycycline and ceftriaxone—cleared the Lyme infection in the study mice. The scientists now hope to test the combination in people with persistent Lyme disease.
“There is a lot of excitement in the field, because we now have not only a plausible explanation but also a potential solution for patients who suffer from persistent Lyme disease symptoms despite standard single-antibiotic treatment,” says study senior author Ying Zhang, MD, PhD, professor in the Department of Molecular Microbiology and Immunology at the Bloomberg School.
Lyme disease afflicts about 300,000 people in the United States every year. It is caused by Borrelia bacteria that live inside common species of ticks and are transmitted to humans by tick bites. Treatment with a single antibiotic—either doxycycline, amoxicillin or cefuroxime—for two to four weeks clears infection and resolves symptoms in most patients. However, some 10 to 20 percent of Lyme patients who are treated continue to suffer persistent symptoms including fatigue, muscle and joint aches, and brain fog that can six months or longer.
This post-treatment Lyme disease syndrome has been controversial among many doctors, in part because studies of these patients usually have failed to show that Borrelia bacteria can be cultured from their blood, especially after treatment—a standard method for revealing the presence of an infection or relapse. However, Borrelia, like many bacteria, can switch under low-nutrient conditions or other stresses from their normal fast-growth mode to variant forms as in “stationary phase” with little or no growth.
Studies also have hinted that these stationary-phase variants can be killed with the right drugs. Research by Zhang and colleagues has shown that a combination of daptomycin, doxycycline and cefoperazone reliably kills cultures of B. burgdorferi that include stationary-phase variant forms.
In this new study, Zhang and colleagues grew stationary-phase B. burgdorferi and isolated two distinct no-growth forms, called microcolony and planktonic forms. They confirmed that these forms are resistant to standard antibiotics such as doxycycline and even two-drug combinations used for treating Lyme disease. They also showed that these stationary-phase forms, compared to normal-growing spiral forms of B. burgdorferi, cause worse Lyme disease-like symptoms in mice—chiefly inflammation and joint-swelling. However, treating these mice with the combination of daptomycin, doxycycline and ceftriaxone effectively eradicated the infection.
“A lot of physicians have been wanting to do clinical trials of antibiotic combinations in post- treatment Lyme disease syndrome patients, and now we have results in animals that support the idea of such trials,” Zhang says.
He and his colleagues are making plans for their own trial of the persister drug combination against post-treatment Lyme disease syndrome. They note that the idea of persister bacteria causing severe and persistent infections with varying susceptibilities to different drugs might apply to other infectious diseases in which symptoms sometimes persist, despite standard treatment.
“Stationary Phase Persister/Biofilm Microcolony of Borrelia burgdorferi Causes More Severe Disease in a Mouse Model of Lyme Arthritis: Implications for Understanding Persistence, Post-Treatment Lyme Disease Syndrome (PTLDS), and Treatment Failure” was written by Jie Feng, Tingting Li, Rebecca Yee, Yuting Yuan, Chunxiang Bai, Menghua Cai, Wanliang Shi, Monica Embers, Cory Brayton, Harumi Saeki, Kathleen Gabrielson, and Ying Zhang.
Funding for the research was provided by the Steven and Alexandra Cohen Foundation, Global Lyme Alliance, LivLyme Foundation, NatCapLyme, and the Einstein-Sim Family Charitable Fund.
The 10-20% being used to identify those with remaining symptoms is inaccurate and NEEDS to change. For a great read explaining this: https://madisonarealymesupportgroup.com/2019/02/25/medical-stalemate-what-causes-continuing-symptoms-after-lyme-treatment/
In short, Microbiologist Holly Ahern recently wrote that the arbitrary label “Post Treatment Lyme Disease Syndrome,” or PTLDS, which the CDC estimates to be 10-20% of patients only truly represents a subgroup of patients who have been diagnosed early, treated with standard short-term antibiotics, and whom remained symptomatic or developed new symptoms. It does not and should not include a third group who were misdiagnosed or undiagnosed beyond the first few weeks of infection. She states estimates based on existing research show this unaccounted for group makes up 30-40% of Lyme disease patients. By combining the PTLDS group with the third group, there are 60% of patients ending up with chronic symptoms, a number that more closely matches my experience as a patient advocate (9) https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/
This is important because 60% is much bigger than 10-20% and reveals the vast suffering and the dire need for research on this neglected subgroup of patients.
Recently, this came out regarding treatment: https://madisonarealymesupportgroup.com/2019/04/17/global-lyme-alliance-doing-kick-butt-research/
Dr. Kim Lewis and his team at Northeastern University, independently, discovered that Disulfiram, used for treating alcoholism, was extremely effective in culture and in mice in to killing burgdorferi in all forms.
This is promising as it won’t destroy the gut like antibiotics.